|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:abstractText |
High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition is one strategy for increasing HDL-C. This study evaluated the lipid-altering efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy or coadministered with atorvastatin in patients with dyslipidemia.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
157
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
352-360.e2
|
|
pubmed:dateRevised |
2009-6-23
|
|
pubmed:meshHeading |
pubmed-meshheading:19185645-Aged,
pubmed-meshheading:19185645-Anticholesteremic Agents,
pubmed-meshheading:19185645-Cholesterol Ester Transfer Proteins,
pubmed-meshheading:19185645-Dose-Response Relationship, Drug,
pubmed-meshheading:19185645-Double-Blind Method,
pubmed-meshheading:19185645-Drug Therapy, Combination,
pubmed-meshheading:19185645-Dyslipidemias,
pubmed-meshheading:19185645-Female,
pubmed-meshheading:19185645-Heptanoic Acids,
pubmed-meshheading:19185645-Humans,
pubmed-meshheading:19185645-Male,
pubmed-meshheading:19185645-Middle Aged,
pubmed-meshheading:19185645-Oxazolidinones,
pubmed-meshheading:19185645-Pyrroles,
pubmed-meshheading:19185645-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
|
|
pubmed:affiliation |
Merck Research Laboratories, Rahway, NJ 07065-0900, USA. daniel_bloomfield@merck.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
